Landscape Capital Management L.L.C. Makes New $721,000 Investment in Guardant Health, Inc. (NASDAQ:GH)

Landscape Capital Management L.L.C. purchased a new position in shares of Guardant Health, Inc. (NASDAQ:GH) during the third quarter, HoldingsChannel reports. The firm purchased 31,448 shares of the company’s stock, valued at approximately $721,000.

Other institutional investors also recently modified their holdings of the company. JNBA Financial Advisors bought a new position in shares of Guardant Health in the 3rd quarter worth about $26,000. Ashton Thomas Securities LLC bought a new position in shares of Guardant Health during the 3rd quarter worth approximately $34,000. Quarry LP acquired a new stake in shares of Guardant Health during the 2nd quarter worth approximately $44,000. Canton Hathaway LLC bought a new stake in shares of Guardant Health in the 2nd quarter valued at $59,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Guardant Health during the second quarter worth $71,000. Institutional investors own 92.60% of the company’s stock.

Analyst Upgrades and Downgrades

GH has been the topic of a number of research analyst reports. UBS Group increased their price objective on shares of Guardant Health from $32.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, August 21st. TD Cowen raised their price objective on Guardant Health from $41.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. The Goldman Sachs Group increased their target price on Guardant Health from $32.00 to $36.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Citigroup upped their price objective on shares of Guardant Health from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Finally, Piper Sandler boosted their target price on shares of Guardant Health from $30.00 to $34.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 13th. One research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.60.

Guardant Health Stock Up 5.4 %

GH opened at $32.65 on Friday. The company has a debt-to-equity ratio of 16.70, a current ratio of 6.22 and a quick ratio of 5.85. Guardant Health, Inc. has a one year low of $15.81 and a one year high of $37.04. The firm has a market capitalization of $4.03 billion, a P/E ratio of -7.70 and a beta of 1.11. The company has a fifty day moving average price of $24.22 and a 200-day moving average price of $26.83.

Guardant Health (NASDAQ:GH) last announced its earnings results on Wednesday, November 6th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.33). Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The business had revenue of $191.48 million during the quarter, compared to the consensus estimate of $170.49 million. During the same quarter in the prior year, the company earned ($0.73) earnings per share. Guardant Health’s revenue was up 33.9% compared to the same quarter last year. Equities research analysts expect that Guardant Health, Inc. will post -3.38 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Meghan V. Joyce sold 2,896 shares of the stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.90, for a total transaction of $86,590.40. Following the transaction, the director now directly owns 7,648 shares in the company, valued at approximately $228,675.20. This represents a 27.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 5.50% of the company’s stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.